Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) CongressBusiness Wire • 09/29/23
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi RivalInvestors Business Daily • 09/18/23
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 08/01/23
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell CarcinomaBusiness Wire • 07/31/23
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host DiseasePRNewsWire • 07/24/23
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic DermatitisBusiness Wire • 07/11/23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its BoardGlobeNewsWire • 06/12/23
Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid CongressBusiness Wire • 05/25/23
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D.Business Wire • 05/08/23
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter SalesInvestors Business Daily • 05/02/23
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/02/23